Not yet recruitingInterventionalPhase 2Last updated Aug 7, 2026

Retlirafusp Alfa Combined With Chemotherapy or Fuzuloparib for Triple-Negative Breast Cancer

Retlirafusp Alfa Combined With Chemotherapy or Fuzuloparib for Triple-Negative Breast Cancer: An Exploratory Clinical Study

Overview

ClinicalTrials.gov ID: NCT07752550
Lead Sponsor: Harbin Medical UniversityOTHER
Brief Summary: To investigate the efficacy and safety of Retlirafusp alfa in combination with chemotherapy or fluzoparib for early-stage and advanced triple-negative breast cancer.
Study Type: Interventional

Status

Overall Status: Not yet recruiting
Start Date: Jul 30, 2026Estimated
Primary Completion Date: Jul 30, 2028Estimated
Completion Date: Jul 30, 2029Estimated

Study Record Dates

First Submitted: Aug 4, 2026
First Submitted that Met QC Criteria: Aug 4, 2026
First Posted: Aug 7, 2026Actual
Last Update Submitted that Met QC Criteria: Aug 4, 2026
Last Update Posted: Aug 7, 2026Actual
Last Verified: Aug 2026

NCT05834582Unknown status

Neoadjuvant Fluzoparib in Germline BRCA-mutated Three-negative Breast Cancer Breast Cancer

NCT06636981Recruiting

All Trans Retinoic Acid Combined with Toripalimab+Chemotherapy for Locally Advanced Inoperable or Metastatic Triple Negative Breast Cancer：a Multi-center, Multi-cohort Phase II Trial

NCT07162051Completed

A Study on the Use of Fluzoparib Combined With Chemotherapy for Neoadjuvant Treatment of HRD-positive, HR+/HER2- Breast Cancer

NCT06533384Recruiting

PARPi or Capecitabine Combined With PD-1 Inhibitors as Adjuvant Therapy in High-risk TNBC

NCT07161791Not yet recruiting

Camrelizumab, Pirfenidone, and Chemotherapy in the Treatment of Advanced Triple-Negative Breast Cancer

NCT04584112Completed

A Study of the Safety, Efficacy, and Pharmacokinetics of Tiragolumab in Combination With Atezolizumab and Chemotherapy in Participants With Triple-Negative Breast Cancer